Dag Nyholm
Professor vid Institutionen för medicinska vetenskaper; Neurologi
- E-post:
- dag.nyholm@neuro.uu.se
- Besöksadress:
- Akademiska sjukhuset
- Postadress:
- Akademiska sjukhuset, ing 85 plan 2
751 85 UPPSALA
Ladda ned kontaktuppgifter för Dag Nyholm vid Institutionen för medicinska vetenskaper; Neurologi
- Akademiska meriter:
- MD PhD, Docent
- ORCID:
- 0000-0001-9776-7715
Mer information visas för dig som medarbetare om du loggar in.
Kort presentation
Dag Nyholm är överläkare och professor i neurologi. Forskningen rör mestadels området rörelsestörningar - särskilt optimering av behandlingar vid Parkinsons sjukdom, men också cervikal dystoni, essentiell tremor, Huntingtons sjukdom, multipel systematrofi och normaltryckshydrocefalus. Projekt pågår även inom andra delar av klinisk neurologi.
Nyckelord
- movement disorders
- neurology
- parkinson´s disease
Biografi
Läkarexamen 1999, Uppsala universitet.
Disputation 2003, Uppsala universitet, Pharmacotherapy for Parkinson's disease - observations and innovations
Docent 2009, Uppsala universitet.
Specialistläkare 2015, Akademiska sjukhuset.
Professor 2022, Uppsala universitet
Forskning
Handledning av pågående doktorandprojekt
Optimering av djup hjärnstimulering vid motorikstörningar. Elena Jiltsova. (Huvudhandledare)
Development of a new biomarker for detection of prodromal Parkinson’s disease. Paul de Roos. (Huvudhandledare)
Biomarkörer i cerebrospinalvätska vid normaltryckshydrocefalus. Madelene Braun. (Huvudhandledare)
Montreal Cognitive Assessment and Cognitive Effects of Interventions in Stroke. Elias Lindvall. (Bihandledare)
Avancerad Parkinsons sjukdom: Aspekter på terapier och icke-motoriska symptom. Sotirios Gregoriou, Lunds universitet (Bihandledare)
Videobaserad analys av motorik vid normaltryckshydrocefalus och Parkinsons sjukdom. Maria Ekblom. (Bihandledare)
Samarbetspartner
Uppsala universitet:
Farmaceutisk biovetenskap, Farmakometri
Folkhälso- och vårdvetenskap, Geriatrik
Folkhälso- och vårdvetenskap, Geriatrik; Molekylär geriatrik/ Rudbecklaboratoriet
Informationsteknologi, Systemteknik
Kemi - BMC, Analytisk kemi
Kirurgiska vetenskaper, Radiologi
Medicinska vetenskaper, Gastroenterologi/hepatologi
Medicinska vetenskaper, Klinisk kemi
Fysioterapi
Medicinska vetenskaper, Neurokirurgi
Medicinska vetenskaper, Klinisk farmakologi
Övriga inom Sverige:
Göteborgs universitet
Högskolan i Dalarna
Karolinska institutet
Linköpings universitet
Lunds universitet
Stockholms universitet
Umeå universitet
Örebro universitet
Media
Dystoni
Föreläsning för Svensk dystoniförening, 2016
https://www.youtube.com/watch?v=s7AQ_PT0vEw&t=2s
Digital hälsa
Current Current Challenges in Biomed-IT, Digital Health 1a, Dag Nyholm
https://www.youtube.com/watch?v=Zo2ToUNyCpA&t=110s
Läkemedel och äldre: Parkinsons sjukdom
Läkemedel och äldre: Parkinsons sjukdom. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/11862
Dystonier
Dystonier. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/11126
Tremor
Tremor. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/11125
Parkinsons sjukdom – behandling i komplikationsfas
Parkinsons sjukdom – behandling i komplikationsfas. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/10165
Parkinsons sjukdom – behandling
Parkinsons sjukdom – behandling. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/10158
Parkinsons sjukdom – symtom, diagnostik och etiologi
Parkinsons sjukdom – symtom, diagnostik och etiologi. Uppsala universitet, Medfarm Play. 2020.
https://media.medfarm.uu.se/play/video/10138
Publikationer
Senaste publikationer
- Comparison of quantitative [11C]PE2I brain PET studies between an integrated PET/MR and a stand-alone PET system (2024)
- Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases (2023)
- Phosphorylated α-synuclein in skin Schwann cells (2023)
- Patients accept therapy using embryonic stem cells for Parkinson's disease (2023)
- Pain in patients with motor neuron disease (2023)
Alla publikationer
Artiklar
- Comparison of quantitative [11C]PE2I brain PET studies between an integrated PET/MR and a stand-alone PET system (2024)
- Levels of inflammatory cytokines MCP-1, CCL4, and PD-L1 in CSF differentiate idiopathic normal pressure hydrocephalus from neurodegenerative diseases (2023)
- Phosphorylated α-synuclein in skin Schwann cells (2023)
- Patients accept therapy using embryonic stem cells for Parkinson's disease (2023)
- Pain in patients with motor neuron disease (2023)
- The Impact of COVID-19 on Parkinson's Disease (2023)
- Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease (2022)
- Higher levels of neurofilament light chain and total tau in CSF are associated with negative outcome after shunt surgery in patients with normal pressure hydrocephalus (2022)
- Trial of Deferiprone in Parkinson’s Disease (2022)
- Patients' views on using human embryonic stem cells to treat Parkinson's disease (2022)
- Attitudes and values among the Swedish general public to using human embryonic stem cells for medical treatment (2022)
- Toward Improved Treatment and Empowerment of Individuals With Parkinson Disease (2022)
- Optimizing Treatment of Parkinson's Disease (2022)
- Levodopa-entacapone-carbidopa intestinal gel infusion in advanced Parkinson's disease (2022)
- Composite attenuation correction method using a 68Ge-transmission multi-atlas for quantitative brain PET/MR. (2022)
- Midbrain area and the hummingbird sign from brain MRI in progressive supranuclear palsy and idiopathic normal pressure hydrocephalus (2022)
- Imaging features associated with idiopathic normal pressure hydrocephalus have high specificity even when comparing with vascular dementia and atypical parkinsonism (2021)
- Personalized Medicine Approach in Treating Parkinson's Disease, Using Oral Administration of Levodopa/Carbidopa Microtablets in Clinical Practice (2021)
- Proenkephalin Decreases in Cerebrospinal Fluid with Symptom Progression of Huntington's Disease (2021)
- An updated calculator for determining levodopa-equivalent dose (2021)
- Effects of Helicobacter pylori on Levodopa Pharmacokinetics (2021)
- Close relationships in Parkinson ' s disease patients with device-aided therapy (2021)
- Pain, disease severity and associations with individual quality of life in patients with motor neuron diseases (2021)
- Initial Experience of the Levodopa–Entacapone–Carbidopa Intestinal Gel in Clinical Practice (2021)
- Motion Sensor-Based Assessment of Parkinson's Disease Motor Symptoms During Leg Agility Tests (2020)
- A multiple motion sensors index for motor state quantification in Parkinson's disease (2020)
- Parkinson's disease - heterogeneous and complex in its clinical presentation. (2020)
- Everyday Occupations and Other Factors in Relation to Mental Well-Being Among Persons With Advanced Parkinson's Disease (2020)
- Real-Life Use of Levodopa/Carbidopa Intestinal Gel in Parkinson's Disease According to Analysis of Pump Data (2020)
- Population pharmacokinetics of levodopa gel infusion in Parkinson's disease (2020)
- Accuracy and precision of zero-echo-time, single- and multi-atlas attenuation correction for dynamic [11C]PE2I PET-MR brain imaging (2020)
- A Phase 2a Trial Investigating the Safety and Tolerability of the Novel Cortical Enhancer IRL752 in Parkinson's Disease Dementia (2020)
- A survey of lifestyle factors in dystonia. (2020)
- Alterations in the tyrosine and phenylalanine pathways revealed by biochemical profiling in cerebrospinal fluid of Huntington's disease subjects (2019)
- Evaluation of a sensor algorithm for motor state rating in Parkinson's disease (2019)
- Sensor-based algorithmic dosing suggestions for oral administration of levodopa/carbidopa microtablets for Parkinson's disease: a first experience. (2019)
- The effect of continuous levodopa treatment during the afternoon hours (2019)
- Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry (2018)
- Differential diagnosis of patients with parkinsonian syndrome using multilinear regression to disease-specific C-11-PE2I-PET templates and classification tree learning (2018)
- A randomized, double-blind, placebo-controlled trial of camicinal in Parkinson's disease. (2018)
- Workforce participation and activities in Parkinson's disease patients receiving device-aided therapy (2018)
- Population pharmacokinetics of levodopa/carbidopa microtablets in healthy subjects and Parkinson’s disease patients (2018)
- Evaluation of zero-echo-time attenuation correction for integrated PET/MR brain imaging-comparison to head atlas and 68Ge-transmission-based attenuation correction (2018)
- Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial (2018)
- Individual dose-response models for levodopa infusion dose optimization (2018)
- A Treatment-Response Index From Wearable Sensors for Quantifying Parkinson's Disease Motor States (2018)
- Verification of a Method for Measuring Parkinson's Disease Related Temporal Irregularity in Spiral Drawings (2017)
- Development of new levodopa treatment strategies in Parkinson’s disease – from bedside to bench to bedside (2017)
- Development of a clinically feasible [11C]PE2I PET method for differential diagnosis of parkinsonism using reduced scan duration and automated reference region extraction. (2017)
- Feasibility of spirography features for objective assessment of motor function in Parkinson's disease (2017)
- Levodopa/carbidopa microtablets in Parkinson’s disease (2017)
- First clinical experience with levodopa/carbidopa microtablets in Parkinson’s disease (2017)
- Levodopa-entacapone-carbidopa intestinal gel in Parkinson's disease (2017)
- Levodopa-carbidopa enteral suspension in advanced Parkinson's disease: clinical evidence and experience (2017)
- Initiation of Levodopa-Carbidopa Intestinal Gel Infusion Using Telemedicine (Video Communication System) Facilitates Efficient and Well-Accepted Home Titration in Patients with Advanced Parkinson's Disease (2017)
- Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinson's disease (2016)
- Validation of Zero-Echo Time PET-MR against stand-alone PET using dynamic dopamine transporter imaging (2016)
- Transcutaneous port for levodopa/carbidopa intestinal gel administration in Parkinson's disease (2016)
- Authors' Reply to Lambarth (2016)
- Levodopa–Carbidopa Intestinal Gel in Patients with Parkinson’s Disease (2016)
- Use of C-11-PE2I PET in Differential Diagnosis of Parkinsonian Disorders (2015)
- Validity and Responsiveness of At-Home Touch Screen Assessments in Advanced Parkinson's Disease (2015)
- Automatic Spiral Analysis for Objective Assessment of Motor Symptoms in Parkinson's Disease (2015)
- A Comparison of Botox 100 U/mL and Dysport 100 U/mL Using Dose Conversion Ratio 1: 3 and 1: 1.7 in the Treatment of Cervical Dystonia (2015)
- A computer vision framework for finger-tapping evaluation in Parkinson's disease (2014)
- Levodopa Fractionation in Parkinson's Disease (2014)
- Continuous drug delivery in Parkinson's disease (2014)
- Validation of parametric methods for [(11)C]PE2I positron emission tomography (2013)
- Computer Vision Methods for Parkinsonian Gait Analysis (2013)
- Automatic and Objective Assessment of Alternating Tapping Performance in Parkinson's Disease (2013)
- Combined fine-motor tests and self-assessments for remote detection of motor fluctuations (2013)
- Spiral drawing during self-rated dyskinesia is more impaired than during self-rated off. (2013)
- Frequent administration of levodopa/carbidopa microtablets vs levodopa/carbidopa/entacapone in healthy volunteers (2013)
- Pharmacokinetics of Levodopa, Carbidopa, and 3-O-Methyldopa Following 16-hour Jejunal Infusion of Levodopa-Carbidopa Intestinal Gel in Advanced Parkinson's Disease Patients (2013)
- Motor fluctuations and Helicobacter pylori in Parkinson's disease (2013)
- Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease (2013)
- Long-term 24-h levodopa/carbidopa gel infusion in Parkinson's disease (2012)
- Continuous delivery of energy or L-dopa: Identifying advantages and limitations of DBS and levodopa-carbidopa intestinal gel in ansence of head-to-head comparisons (2012)
- Parametric methods for [11C]PE2I positron emission tomography (2012)
- Treatment of advanced Parkinson's disease with levodopa/carbidopa intestinal gel is associated with improvements in Hoehn and Yahr stage (2012)
- Update on levodopa/carbidopa intestinal gel infusion (2012)
- Duodopa(®) treatment for advanced Parkinson's disease (2012)
- Complexity of Motor Response to Different Doses of Duodenal Levodopa Infusion in Parkinson Disease (2012)
- Levodopa infusion combined with entacapone or tolcapone in Parkinson disease (2012)
- Levodopa/carbidopa intestinal gel infusion long-term therapy in advanced Parkinson's disease (2012)
- Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers (2012)
- Levodopa fractionation in Parkinson's disease (2012)
- Interim analysis of long-term intraduodenal levodopa infusion in advanced Parkinson disease (2012)
- Clinical Experience of Dose Conversion Ratios Between 2 Botulinum Toxin Products in the Treatment of Cervical Dystonia (2012)
- Validation of a home environment test battery for supporting assessments in advanced Parkinson’s disease (2012)
- Long-term efficacy and safety with continuous dopaminergic stimulation pump treatments in Parkinson's disease (2011)
- A web application for follow-up of results from a mobile device test battery for Parkinson’s disease patients (2011)
- Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint (2011)
- A pharmacokinetic-pharmacodynamic model for duodenal levodopa infusion (2011)
- Large differences in levodopa dose requirement in Parkinson's disease (2010)
- Circadian rhythmicity in levodopa pharmacokinetics in patients with Parkinson disease (2010)
- Patient-Perceived Retrospective Outcome of Duodenal Levodopa Infusion in Advanced Parkinson´s Disease (2010)
- Clinical, neuroimaging and neurophysiological features in addicts with manganese-ephedrone exposure (2010)
- A home environment test battery for status assessment in patients with advanced Parkinson's disease (2010)
- A new computer method for assessing drawing impairment in Parkinson's disease (2010)
- Short-Term Cost and Health Consequences of Duodenal Levodopa Infusion in Advanced Parkinson's Disease in Sweden (2009)
- Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations (2009)
- Soft tissue-anchored transcutaneous port attached to an intestinal tube for long-term gastroduodenal infusion of levodopa/carbidopa in Parkinson disease (2009)
- Irregular gastrointestinal drug absorption in Parkinson's disease (2008)
- Enteral Levodopa/Carbidopa infusion in advanced Parkinson disease (2008)
- Neurologi i förvandling - från diagnostik till terapeutisk disciplin (2008)
- The rationale for continuous dopaminergic stimulation in advanced Parkinson's disease (2007)
- Irreversible motor impairment in young addicts - ephedrone, manganism or both? (2007)
- Long-term 24-hour duodenal infusion of levodopa (2006)
- Enteral levodopa/carbidopa gel infusion for the treatment of motor fluctuations and dyskinesias in advanced Parkinson's disease (2006)
- Pharmacokinetic optimisation in the treatment of Parkinson's disease: an update (2006)
- Outcome prediction of enteral levodopa/carbidopa infusion in advanced Parkinson's disease (2006)
- Infusing levodopa to stabilise blood levels (2005)
- Long-term 24-hour duodenal infusion of levodopa (2005)
- Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease (2005)
- New developments in levodopa therapy (2004)
- Levodopa infusion therapy in Parkinson Disease (2004)
- Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson's disease (2004)
- An automatic dose dispenser for microtablets (2003)
- Optimizing levodopa pharmacokinetics (2003)
- Levodopa pharmacokinetics and motor performance during activities of daily living in parkinsonian patients on individual drug combinations (2002)
- Levodopa pharmacokinetics and motor performance during activities of daily living in patients with Parkinson's disease on individual drug combinations (2002)
- Duodenal levodopa infusion in Parkinson’s disease – long-term experience (2001)
- CSF Proenkephalin decreases with the progression of Huntington's disease
- Wireless real-time electronic data capture for self-assessment of motor function and quality of life in Parkinson’s disease
- Composite 68Ge attenuation correction for quantitative brain PET/MR
- Comparison of quantitative [11C]PE2I PET scans acquired on PET/MR and stand-alone PET
Böcker
- Neurologi (2020)
- Neurologi (2012)
- Från Alzheimer till övervikt (2007)
- Pharmacotherapy for Parkinson's Disease - Observations and Innovations (2003)
Kapitel
- Rörelsestörningar (2020)
- Neurologisk symtomlära (2020)
- Den neurologiska konsultationen (2020)
- Funktionella neurologiska sjukdomar (2020)
- Stochastic anomaly detection in eye-tracking data for quantification of motor symptoms in Parkinson's disease (2015)
- Neurologisk symtomlära (2012)
- Den neurologiska undersökningen (2012)
- Akutneurologi (2012)
- Rörelsestörningar (2012)
- Alternatives to oral levodopa Duodopa - continuous levodopa administration (2007)
Konferenser
- Unsupervised Learning from Motion Sensor Data to Assess the Condition of Patients with Parkinson's Disease (2019)
- Using measurements from wearable sensors for automatic scoring of Parkinson's disease motor states (2017)
- Feasibility of Spirography Features for Objective Assessment of Motor Symptoms in Parkinson's Disease (2015)
- Visualization of spiral drawing data of patients with Parkinson's disease (2014)
- Stochastic anomaly detection in eye-tracking data for quantification of motor symptoms in Parkinson's disease (2013)
